

22 October 2019

ASX Announcement

Positive study results for Pentrox[®] demonstrating superiority over Standard of Care for acute trauma pain treatments in patients across Europe

Medical Developments International Limited (ASX: MVP) is delighted to announce that data across 11 abstracts of studies conducted throughout Europe and presented at the EUSEM Congress on October 12th to 14th 2019 have demonstrated multiple positive results of Pentrox[®] including:

- Pentrox demonstrated superiority over intravenous (IV) morphine, paracetamol, ketoprofen and NSAIDS within a trauma setting ^{1,2,3,4}
- Pentrox added to standard of care (SoC) demonstrates superiority over SoC plus placebo within a trauma setting ⁵
- Pentrox was successful in dislocation injuries, ^{6,7} and resulted in reduced time spent in the Emergency Departments - improving the patient experience and reducing crowding within the ED ⁶
- Other studies confirmed previously published data ^{8,9}; that Pentrox is an efficacious, well tolerated/safe and rapidly acting analgesic in trauma settings ^{8,9,10,11}
- Studies commonly reported that Pentrox exceeded patient/clinician expectations and or resulted in a high degree of treatment satisfaction from patients and health care professionals ^{1,2,3,4,12,13}
- Pentrox was generally well tolerated across the studies, with most adverse event (AEs) being mild and transient ^{3,4,5,10,12,13}.

MVP CEO, Mr. John Sharman said, “We are delighted with the results of these recent European clinical trials demonstrating superiority of Pentrox[®] over Standard of Care treatments (intravenous (IV) morphine, IV paracetamol, ketoprofen or NSAIDS) within the acute trauma setting. This reinforces the global potential for Pentrox[®] as a simple, fast and effective non-opioid pain medication.”

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 (3) 9547 1888

References

- 1 A Voza, Serra S, Ruggiano G, Fabbri A, *et al.* Methoxyflurane versus standard analgesic treatment for acute trauma-related pain in the emergency setting: results of a randomised, controlled study in Italy (MEDITA). Presented at EUSEM 2019. Abstract #18647, Poster P37.
- 2 Capilla Pueyo R, Fernandez Alonso C, Garcia S, *et al.* Methoxyflurane, an efficient and well tolerated analgesic for elderly patients, compared with standard analgesic treatment: subgroup analysis of a phase IIIb randomised, controlled trial (InMEDIATE). Presented at EUSEM 2019. Abstract #18659 - OP014.
- 3 Fernández Alonso C, Garcia Collado S, Carballo Cardona C, *et al.* Low dose of inhaled Methoxyflurane: more effective and rapid-acting than standard analgesic treatment, also for severe trauma-related pain: subgroup analysis of a randomised controlled trial (InMEDIATE). Presented at EUSEM 2019. Abstract #18660 - SP090.
- 4 Capilla Pueyo R, Carballo Cardona C, Fernandez Alonso C, *et al.* Low dose of inhaled methoxyflurane is more effective with higher patient and clinician satisfaction than first-step intravenous analgesic treatment for acute trauma-related pain: subgroup analysis of a phase IIIb randomised controlled trial (InMEDIATE). Presented at EUSEM 2019. Abstract #18661 - OP015.
- 5 Ricard-Hibon A, Lecoules N, Savary D, *et al.* A randomised, double blind placebo-controlled study of methoxyflurane plus standard of care analgesia versus placebo plus standard of care analgesia for moderate to severe pain associated with trauma (The PenASAP Study). Presented at EUSEM 2019. Abstract #19302 - OP008.
- 6 A.Mir-Kohler, C.L Rial, S. Suresh, R. Ferguson, L. Hunter. Impact of methoxyflurane in shoulder dislocation on patient care and crowding - Can the green whistle improve our care and our flow? EUSEM presentation, Abstract #19322
- 7 R Austin, L Gangadharan, N Whitlock (Bedford, UK). Methoxyflurane in the emergency department; a brief summary of our experiences. EUSEM presentation # OP006
- 8 Coffey F, Wright J, Hartshorn S, *et al.* STOP!: a randomised, double-blind, placebo-controlled study of the efficacy and safety of methoxyflurane for the treatment of acute pain. *Emerg Med J* 2014;31:613-618.
- 9 Coffey F, Dissmann P, Mirza K, *et al.* Methoxyflurane Analgesia in Adult Patients in the Emergency Department: A Subgroup Analysis of a Randomized, Double-blind, Placebo-controlled Study (STOP!) *Adv Ther* 2016;33:2012-2031.
- 10 I. Srzić, V.N. Adam. Efficacy of methoxyflurane in analgesia for acute trauma related pain. EUSEM presentation Abstract #318670.
- 11 L Miraillet, F Moustafa (Clermont-Ferrand), C Bonhomme, S Greck, S Loiseau, L Jainsky, D Gonalez, J Raconnat, J Schmidt Management of monotraumatic pain with methoxyflurane in emergency department. EUSEM presentation Abstract #18120
- 12 M Zlicar (L, Slovenia), A M Brecko. Self-inhaled methoxyflurane for analgesia in trauma patients: a case series. EUSEM presentation #18664
- 13 A Killianova, V Kizyma (K, Slovakia), E Havlikova. Effects of methoxyflurane as an analgesic agent for trauma management in the pre-hospital settings in Slovakia. EUSEM presentation Abstract # OP025

About Pentrox

Pentrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Pentrox has been used safely and effectively for more than 40 years in Australia with excess of 5.0 million units sold. There is growing interest in Pentrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox[®], a fast-acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.